Antibodies

Antibodies in mucous membranes may be key in protecting against SARS-CoV-2 variants, pointing to the need for COVID-19 vaccines that target these antibody responses.

A*STAR researchers tackle the challenge of creating therapeutic antibodies that effectively kill tumours and are also easily scalable in manufacturing settings.

A*STAR researchers create a next-generation, ultrasensitive COVID-19 rapid test powered by gold nanoparticles.

Research reveals the safety of mRNA COVID-19 vaccines for breastfeeding mothers and the potential of passing immune protection to the baby.

Data shows that antibodies produced as part of the COVID-19 immune response can neutralize a more transmissible variant of SARS-CoV-2.

Some neutralizing antibodies against SARS-CoV-2 may heighten lung tissue damage from COVID-19, an A*STAR study finds.

Using a large-scale siRNA screen and CRISPR-Cas9 technology, researchers have pinpointed genes that can enhance antibody production in Chinese hamster ovary cells.

Using flow cytometry, researchers have developed a sensitive and specific test for COVID-19 that can identify asymptomatic carriers.

A multifaceted study by the Singapore 2019 Novel Coronavirus Outbreak Research team is filling in some of the gaps left in the urgent quest to understand COVID-19 infection.

A new test manufactured by A*STAR’s Diagnostics Development Hub in partnership with Duke-NUS Medical School could reveal if an individual is likely immune to COVID-19.

A novel targeting strategy may make pave the way for effective cancer immunotherapy against previously ‘undruggable’ targets.

Understanding how closely related coronaviruses circulate seasonally could impact the timing of vaccination against SARS-CoV-2.